Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enzomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Foundation Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Foundation Medicine, Sumitomo Collaborate on Acute Leukemia Treatment
Details : The collaboration aims to develop the FoundationOne Heme platform as a companion diagnostic to identify patients with AML with a NPM1 mutations for potential treatment with DSP-5336 (enzomenib).
Product Name : DSP-5336
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 18, 2025
Lead Product(s) : Enzomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Foundation Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
